Centre National De La Recherche Scientifique

Universitè De Montpellier

Université Pierre Et Marie Curie

Universite Montpellier 2

Université Montpellier II

Naomi Taylor

Marc Sitbon

Felix Jinhyun Kim

Sandrina Kinet

Jean-Luc Battini

Nicolas Gabriel Albert Manel

Jean-Luc Georges Laurent Battini

David Klatzmann

Nicolas Manel

Marcos Steinberg

Gilles Marodon

Cedric Mongellaz

Oumeya Adjali

Chantal Jacquet

A method for the identification and quantification of the expression of membrane receptors present on the surface of target cells using at least two soluble receptor binding ligands derived from the soluble part of the glycoprotein of an enveloped virus that interacts with a cellular cognate receptor, the receptor binding ligand containing a part or the totality of one of the receptor binding domains (RBD) of the glycoprotein, and the soluble receptor binding ligand being liable to interact with the at least one membrane receptor of a target cell, for the identification and quantification of the expression of membrane receptors present on the surface of target cells, the identification and quantification taking place at a given time or during a given time interval, and allowing the determination of a physiological state of the target cell.

Receptor binding ligands, their use in the detection of cells with biological interest

The present application relates to polypeptides derived from the soluble part of the glycoprotein of the enveloped virus of Primate T-cell leukemia virus (PTLV), or fragments or variants thereof named receptor binding domain ligands (RBD) selected for their ability to bind specifically to the nutrient transporter GLUT1.

GLUT-1 as a receptor for HTLV envelopes and its uses

The invention relates to the use of the ubiquitous vertebrate glucose transporter GLUT1, or of fragments or sequences derived thereof, for the in vitro diagnosis of cancers, when used as a tumor marker, or for the screening of compounds useful for the preparation of drugs for the prevention or the treatment of pathologies linked to an infection of an individual with a PTLV, or pathologies linked to an overexpression of GLUT1 on cell surfaces, or the in vitro detection of GLUT1 on cell surfaces. The invention also relates to pharmaceutical compositions containing GLUT1, or fragments or sequences derived thereof, and to their uses such as in the frame of the prevention or the treatment of pathologies linked to an infection of an individual with a PTLV.

Glut-1 as a receptor for HTLV envelopes and its uses

Growing community of inventors

Montpellier, France

Naomi Taylor